Andrea Treyer

6PUBLICATIONS
10CO-AUTHORS
Biomolecular modelling and designBasic pharmacologyCheminformatics and quantitative structure-activity relationshipsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 27, 2021
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.

Chiara Borsari, Erhan Keles, Andrea Treyer

|Nov 09, 2020
4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.

Chiara Borsari, Erhan Keles, Denise Rageot

|Nov 09, 2019
A Cell-Free Approach Based on Phospholipid Characterization for Determination of the Cell Specific Unbound Drug Fraction (fu,cell).

Andrea Treyer, Sandra Walday, Hinnerk Boriss

|Jun 20, 2019
Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies.

Andrea Treyer, Mohammed Ullah, Neil Parrott

|May 01, 2018
Intracellular Drug Bioavailability: Effect of Neutral Lipids and Phospholipids.

Andrea Treyer, André Mateus, Jacek R Wiśniewski

|Dec 09, 2015
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.

L Quteineh, P-Y Bochud, D Golshayan

Pageof 1

Frequent Collaborators

2 joint publications

Pär Matsson

2 joint publications

Chiara Borsari

2 joint publications

Matthias Hamburger

2 joint publications

Matthias P Wymann